On heels of series C extension, RAPT Therapeutics files for IPO

Just weeks after topping off its series C round, Flexus spinout RAPT Therapeutics Inc. (South San Francisco, Calif.) has filed to raise up to $86.3 million in an IPO on NASDAQ underwritten by BofA Merrill Lynch, Wells Fargo Securities, BMO Capital Markets and UBS Investment Bank.

The company’s most advanced programs are antagonists of chemokine CCR4: FLX475 and RPT193...